NCT04357756View on ClinicalTrials.gov

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions
Advanced Solid Tumor
Interventions
DRUG

YH001

YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.

DRUG

Toripalimab

Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.

Trial Locations (3)

2148

Blacktown Hospital, Blacktown Cancer and Haematology Centre, Blacktown

2217

St George Private Hospital, Kogarah

3199

Peninsula & South Eastern Haematology and Oncology Group, Frankston

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY

NCT04357756 - A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter